The Hypocalcemic Effects of Actinomycin D and Mithramycin by Reyes, Eduardo L. & Talley, Robert W.
Henry Ford Hospital Medical Journal
Volume 18 | Number 2 Article 6
6-1970
The Hypocalcemic Effects of Actinomycin D and
Mithramycin
Eduardo L. Reyes
Robert W. Talley
Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health
Commons
This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry
Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons.
Recommended Citation
Reyes, Eduardo L. and Talley, Robert W. (1970) "The Hypocalcemic Effects of Actinomycin D and Mithramycin," Henry Ford Hospital
Medical Journal : Vol. 18 : No. 2 , 115-120.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol18/iss2/6
Henry Ford Hosp. Med. Journal 
Vol. 18, No. 2, 1970 
The Hypocalcemic Effects of Actinomycin D 
and Mithramycin 
Eduardo L. Reyes, M.D.* and Robert W. Talley, M.D.** 
Both actinomycin D and mithramycin are useful agents in the treatment of cancer. 
They can also produce hypocalcemia, a comparatively rare phenomenon in cancer. 
Two such cases are presented in detail. Neither patient had the classic symptoms of 
hypocalcemia. Instead, the clinical picture was more compatible with hypercalce-
mia. The mechanism of action of each drug is explained; therapeutic implications 
are made with regards to their synergistic effects when used in combination with 
the standard calcium-lowering agents. Attention is drawn to the inhibitory action of 
these two agents on the calcium-mobilizing effect of the parathyroid hormone. The 
hypocalcemic effects of these two drugs are peripheral and not due to inhibition of 
parathyroid hormone synthesis. Because of their potentially fatal biochemical side 
effects, extreme caution is advocated in their use. 
Hypercalcemia is a common medi-
cal emergency in patients with neo-
plastic disease, either as a result of the 
malignancy or as a result of therapy. 
Hypocalcemia, however, is a relatively 
rare phenomenon in a patient with can-
cer. Conditions unrelated to cancer can 
give rise to hypocalcemia, eg, rickets, 
osteomalacia, chronic renal failure, 
idiopathic hypoparathyroidism as a 
postoperative complication of thyroid-
ectomy, and moniliasis of the parathy-
roid gland.''^ Neoplasms may also 
cause hypocalcemia dhectly or as a re-
sult of their associated complications. 
of 
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For example, medullary carcinoma of 
the thyroid may produce hypocalcemia 
by secretion of large amounts of thyro-
calcitonin, which is a hypocalcemic fac-
tor.3 Hypocalcemia may also occm: 
spontaneously in lung tumors, and has 
been described in carcinoma of the 
prostate due to sequestration of calcium 
into the areas of osteoblastic meta-
stases.*'^  Breast cancer which has re-
sponded dramatically to therapy may 
also result in hypocalcemia by relative-
ly rapid deposition of calciiun in lytic 
areas in the bone.* Indirectly, other 
conditions associated with cancer may 
also produce hypocalcemia, eg, hypoal-
buminuria due to severe debilitation 
and chronic malnutrition, malabsorp-
tion syndrome which sometimes ac-
companies lymphomas, and chronic 
renal failure due to secondary meta-
stases to the kidney. 
Various drugs such as steroids," 
115 
Reyes and Talley 
phosphates, sulfates, ethylene diamine-
tetriacetate (EDTA), and thyrocalci-
tonin — which lower serum calcium 
levels — have been used in the man-
agement of hypercalcemia. 
This paper will present the compli-
cations of hypocalcemia induced by 
actinomycin D and mithramycin in two 
patients. The mechanism of action of 
the drugs wiU be discussed in relation 
to the homeostasis of calcium meta-
bolism. 
Case Reports 
Case I 
H.W., a 41-year-old white male had a 
thoracotomy in February, 1968, for an un-
differentiated carcinoma of the right lung. 
Following diagnosis, the patient developed 
lytic osseous metastases to the left tibia and 
left ischium. These responded well to cobalt 
therapy. He had a persistent leucocytosis, 
with no clinical infection. In December, 
1968, the patient complained of dull discom-
fort in the right rib cage, progressive weak-
ness, anorexia, and weight loss. Persistence 
of this pain necessitated admission to the 
hospital on January 10, 1969. 
At time of admission, pertinent physical 
findings revealed a thin middle-aged man 
complaining of weakness and pain in the 
right lateral rib cage. Blood pressure was 
120-80, pulse 80/minute and regular, and 
temperature was 100.2°F. Except for tender-
ness in the well-healed right thoracotomy 
scar, a 3 X 3 cm firm tender mass over the 
left ischium, and prominence of the middle 
portion of the tibia, the physical examina-
tion was not unusual. 
Pertinent laboratory findings were: hemo-
globin (Hgb) 10 gm/100 cc; white blood count 
(WBC) 17,000/cu mm; platelet count 524,-
300/cu mm; polymorphonuclear leucocytes 
82%, lymphocytes 11%, bands 1%; urinaly-
sis normal; fasting blood sugar (FBS) 105 
mg/100 cc; urea nitrogen 12 mg/100 cc; 
alkaline phosphatase 6.8 Bodansky units; 
total bilirubin 0.64 mg/100 cc; direct bili-
rubin 0.32 mg/100 cc; serum calcium 11.3 
mg/100 cc, phosphate 3.6 mg/100 cc, serum 
glutamic oxaloacetic transaminas3 (SGOT) 
15 units, lactic dehydrogenase (LDH) 260 
units; albumin 3.07 gm/100 cc; and globu-
lin 0.43%,a„ globulin 1.31 gm%, /3 globulin 
1.09 gm%, and 7 globulin 1.97 gm%. Iliac 
crest bone marrow aspiration revealed a ME 
ratio of 11.2:1, and decreased normoblasts 
but no evidence of tumor cells. The electro-
cardiogram (EKG) was within normal limits. 
X-rays of the chest revealed a superior 
mediastinal mass and a postoperative de-
formity of the fourth right rib. Skeletal x-
rays demonstrated a lytic lesion of the left 
ischium and left tibia. 
Since the patient had extensive metastatic 
disease with recurrence of lesions previously 
radiated, he was considered a candidate for 
chemotherapy with vincristine and antino-
mycin D." The program of therapy was 3.7 
mg of vincristine on the first day with 0.7 
mg of actinomycin D on the next three days. 
Late during the second day of therapy, he 
developed chills and fever. However, the fol -
lowing day his temperature returned to nor-
mal. At this time, he developed tachycardia, 
tachypnea and anxiety. On the fourth day, 
these symptoms increased in severity and the 
deep tendon reflexes were absent. An EKG 
revealed only sinus tachycardia. The serum 
electrolytes were: sodium 120 mEq/L, po-
tassium 3.6 mEq/L, chlorides 86 mEq/L, 
carbon dioxide 17 mEq/L, and serum cal-
cium 6.8 mg/100 cc. The serum enzymes, 
which had been normal prior to chemo-
therapy, were: SGOT of 550 units, L D H 
4,750 units and creatine phosphokinase 
(CPK) 189 units. The Hgb was 10.4 gm/100 
cc; WBC 14,700/cu mm, and platelet count 
50,000/cu mm. On the fifth day (one day 
after completion of the course of therapy) 
he became weak and lethargic, and com-
plained of nausea and dryness of the mouth. 
Neurological examination again revealed the 
absence of deep tendon reflexes but no evi-
dence of increased muscular irritability or a 
positive Chvostek's sign. At this time, the 
serum calcium had fallen to 5.2 mg/100 cc. 
A few hours later, the patient lapsed into a 
coma. Despite therapy with 10 cc of 10% 
calcium gluconate hourly for four doses, he 
deteriorated and died. The blood pressure 
was normal and stable until one hour prior 
to death. 
At autopsy no evidence of acute myo-
cardial infarction or pulmonary embolism 
was found. There was a tumor in the right 
upper lobe infiltrating the pleura, superior 
mediastinum, esophageal serosa, adventitia 
of the aorta, and periosteum of the adjacent 
thoracic vertebra. There was also tumor in-
volvement of the left ischium and left tibia. 
The parathyroid glands were within normal 
limits. 
Case II 
G.O., a 27-year-old white male, was re-
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ferred to Henry Ford Hospital on June 19, 
1966, for chemotherapy of metastatic em-
bryonal carcinoma of the testis. He had un-
dergone an orchiectomy in October, 1964, at 
another institution, followed by radio therapy 
to pelvic and para-aortic nodes. An ab-
dominal mass and ascites developed in Feb-
ruary, 1966, but treatment with cyclophos-
phamide and vinblastine resulted in a brief 
regression. Pertinent physical findings at time 
of admission were: a mass measuring 7 x 8 
cm in the left supraclavicular area, dullness 
to percussion of the bilateral chest, hepa-
tomegally 8 cm below the right costal mar-
gin, and a firm, hard 15 x 13 cm mass in the 
left upper abdomen. 
Pertinent initial laboratory findings were 
as follows: Hgb 14.3 gm/100 cc; WBC 18,-
000/cu mm; platelet count 350,000/cu mm; 
neutrophils 84%; lymphocytes 9%; mono-
cytes 1%; bands 6%. Urinalysis showed spe-
cific gravity to be 1.026, albumin -)-2, oc-
casional epithelial cells, RBC 10-12. Serum 
alkaline phosphatase was 7.4 Bodansky 
units; serum bilirubin 1.6; serum calcium 10 
mg/100 cc; and urea nitrogen 45 mg/100 
cc. X-ray films of the chest revealed bilat-
eral pleural effusion and enlarged media-
stinal nodes. Upper gastrointestinal study re-
vealed a complete obstruction of the fourth 
portion of the duodenum by a large retro-
peritoneal mass, and an intravenous pyelo-
gram revealed minimal hydronephrosis bi-
laterally. 
On June 21, 1968, the patient was started 
on a course of mithramycin 1.75 mg/day 
given in an 8-hour intravenous infusion. His 
serum calcium fell to 8.6 mg/100 cc the 
following day from an initial level of 10 mg/ 
100 cc prior to therapy. This continued to 
fall steadily so mithramycin was discontin-
ued after nine days. Even though his serum 
calcium level fell to 6.2 mg/100 cc, the 
patient manifested no increased muscular ir-
ritability or other signs and symptoms of 
classic hypocalcemia. The serum urea nitro-
Figure 1 
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Changes in serum calcium and phosphate in 
Case #2 (G. O.) with mithramycin therapy. 
gen rose progressively to 72 mg/100 cc. A 
slight decrease was noted in the size of the 
cervical and abdominal mass following 
mithramycin therapy. The serum calcium 
gradually returned to normal (Fig 1) even 
though the serum urea nitrogen increased 
slowly to 90 mg/100 cc 14 days after com-
pletion of therapy. By that time the serum 
calcium had returned to a normal level of 
10.2 mg/100 cc. Because of the persistent in-
testinal obstruction the patient's condition 
deteriorated and he died. 
The autopsy revealed bilateral broncho-
pneumonia and metastases to the para-aortic 
and mediastinal nodes, both adrenals, liver, 
left kidney, vertebra, and left cervical nodes. 
The parathyroids were normal. 
Discussion 
Even though the exact etiology of the 
hypocalcemia in these two patients was 
not conclusively proven, the most likely 
explanation was the effect on calcium 
homeostasis by the two chemothera-
peutic agents employed. The time re-
lationship between drug administration 
and the onset of hypocalcemia favors 
this; also the fact that these patients 
had high calcium levels (Case f l — 
H.W.) and a normal serum calcium 
prior to therapy (Case #11 — CO.). In 
both cases, the patients had none of the 
signs frequently associated with hypo-
calcemia such as increased muscular 
irritability and hyperactive reflexes. On 
the contrary, the signs and symptoms 
could be confused with hypercalcemia. 
However, part of the symptomatology 
of Case #1 could be explained on the 
basis of metabolic acidosis and low 
sodium, chlorides, and potassium which 
may account for the hyperventilation as 
well as lethargy and areflexia. Vincris-
tine may also have contributed to the 
areflexia. However, there are no re-
ported instances of hypocalcemia oc-
curring with vincristine therapy. The 
markedly elevated serum enzymes may 
have resulted from necrosis of normal 
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and/or tumor tissue caused by these 
agents. 
Actinomycin D, an antibiotic, was 
first discovered by Waksman and 
Woodruff in 1940 and found to be an 
effective antibacterial agent, but it is 
too toxic to be used clinically as an 
antibacterial agent, Antinomycin 
produces selective toxicity to the bone 
marrow, lymphoid tissue, and intestinal 
epithelium, and in this respect is similar 
to other cancer chemotherapeutic 
agents.8 In humans, antinomycin D has 
also been found to be effective in treat-
ment of neuroblastomas, Wilm's tumor, 
choriocarcinoma, and testicular neo-
plasms.i» The combination of antino-
mycin D and vincristine has been re-
ported to be effective in the therapy 
of lung cancer.'^  
This agent has also been found to 
produce profound biochemical effects 
including the antagonism of the action 
of parathyroid hormones." Antino-
mycin binds to guanine of the deoxyri-
bonucleic acid (DNA) chain, thus m-
hibiting the synthesis of messenger ribo-
nucleic acid (MRNA). With MRNA 
synthesis inhibited, further RNA syn-
thesis is blocked.13 Although the exact 
mechanism of interference with para-
thyroid hormonal action is unclear, it is 
believed to depend upon induction of 
an enzyme system which blocks para-
thormone or Vitamin D action.^'i^ 
Parathormone induces the synthesis of 
MRNA which regulates enzyme pro-
duction. Actinomycin D probably does 
not interfere with the synthesis of hor-
mones but blocks peripheral action. In 
animal experiments, actinomycin pre-
vents serum calcium elevations m Vita-
min D-deficient rats given either Vita-
min D or parathyroid hormone, i^ -ie 
It is generally accepted that the para-
thyroid hormone influences the kidneys, 
gastrointestinal tract, and (more pro-
foundly) bone. Vitamin D has a similiar 
action, increasing the permeability of 
the intestinal mucosa to calcium^^ and 
also causing morphologic bone 
changes. 1* Actinomycin D is antago-
nistic to these two effects of Vitamin D 
because it inhibits the calcium transport 
system in the gastrointestinal tracfi* 
and suppresses hypercalcemia and 
morphologic bone changes induced by 
the vitamin." i5.i7 
Previous experiments also have 
shown the inhibitory action of antino-
mycin D on the calcium-mobUizing ef-
fect of the parathyroid hormone.i^'i^'i^ 
It seems that actinomycin D blocks this 
effect on the bone but is not effective 
against the phosphoturic action of the 
parathyroid hormone. To further con-
firm the hypocalcemic effect of actino-
mycin D, it has been shown that re-
covery from hypocalcemia is delayed 
in rats treated with actinomycin D after 
administration of thyrocalcitonin.^" The 
hypocalcemic effect of actinomycin D 
is usually delayed from 7 to 12 hours 
after administration. A hypothesis of-
fered for this speculates that, with the 
inhibition of a parathyroid hormone, 
thyrocalcitonin and steroids would be 
free to exert their effects unopposed, 
Mithramycin, another antibiotic, also 
produces hypocalcemia. Historically, 
this drug was derived from an Actino-
mycete culture belonging to the genus 
Streptomyces. It was first shown to be 
active against HeLa ceUs in tissue cul-
ture, adenocarcinoma 755 as well as 
gram positive bacteria in 1960.^ 0 In the 
same year, Curreri and Ansfield pub-
lished the first clinical evaluation of the 
drug in solid tumors, reporting regres-
sions in two patients. Toxic effects 
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noted were nausea, vomiting, acute 
renal failure, and hematopoietic toxicity 
of severe thrombocytopenia.-^ There 
was no mention of hypocalcemia. 
Parker et al gave the drug to 19 
patients in 1960 and formed the same 
conclusions.— In 1963, Koffman re-
ported the results of therapy usmg the 
drug in 84 patients, with regressions 
observed in six patients. Besides the 
usual side effects noted by previous in-
vestigators, he reported hypocalcemia 
in two patients.-^ In 1965, Brown and 
Kennedy also noted significant reduc-
tion in serum calcium and phosphorus, 
with one patient developing sympto-
matic hypocalcemia.-* In 1966, Koons 
also encountered hypocalcemia in his 
patients.-'' In 1968, Ream reported re-
gressions in 9 of 26 evaluable patients. 
Three of his patients developed hypo-
calcemia, two of them symptomatic and 
the other one asymptomatic^^ Talley 
also noted hypocalcemia (less than 8 
mg%) in 10 of 51 patients given this 
drug for aU types of solid tumors.-^ 
Also, none of these patients had symp-
toms suggestive of hypocalcemia but 
many had symptoms that were more 
suggestive of hypercalcemia. 
Mithramycin has also been shown to 
inhibit RNA synthesis. Most probably 
this is also accomplished by binding to 
DNA like antinomycin D.-'^  With this 
inhibition, the enzyme system neces-
sary for hormone action is also 
blocked. The hypocalcemic action of 
mithramycin has been reported in a 
controlled study by Parsons.-* Patients 
with cancer, given mithramycin, 
showed a reduction in urinary calciimi 
reflecting a decrease in serum calcium. 
Urinary hydroxyproline excretion was 
also diminished thereby ruling out the 
possibility of rapid bone repair.-* He 
also suggested that mithramycin might 
block the osteolytic sterols. 
Summary 
Two patients are reported with hypo-
calcemia, one secondary to actinomy-
cin D and one incidental to mithramy-
cin. Neither patient had the classic 
symptoms of increased muscular irri-
tability associated with hypocalcemia. 
Instead, the clinical picture was more 
compatible with hypercalcemia. The 
mechanism of action of these two drugs 
is identical. Both inhibit MRNA pro-
duction which is necessary for enzyme 
synthesis. Such enzyme synthesis is 
vital for hormonal action. The hypo-
calcemic effects of these two drugs are 
peripheral and not due to inhibition of 
parathyroid hormone synthesis. Review 
of the literature shows that these drugs 
have an antagonistic action on the hy-
percalcemic effects of parathyroid hor-
mone and Vitamin D in laboratory ani-
mals. Because of this easily unrecog-
nized complication, attention should be 
directed toward biochemical side ef-
fects as well as known bone marrow 
toxic effects. Therapeutically, actino-
mycin D or mithramycin might be used 
cautiously in the treatment of hyper-
calcemia when other accepted modali-
ties of therapy have failed. 
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